The Oncologist 2008, 3 (suppl 1) : 5–12. 3. Barlesi F, Pujol JL, Daures J-P: Should chemotherapy (Cx) for advanced non-small cell lung cancer (NSCLC) be platinum-based? a literature-based meta-analysis of randomized trials. J Clin Oncol 2005, 23 (16s) : 673s. 4. D’Addario G, Pintilie M, Leighl NB, Fied R, Gerny T,

Shepherd FA: Platinum-based versus non platinum-based chemotherapy in advanced non-small-cell lung cancer: a meta-analysis of the published literature. J Clin Oncol 2005, 23 (13) INCB028050 cost : 2926–2936.PubMedCrossRef 5. McCulloch M, See C, Shu XJ, Broffman M, Kramer A, Fan WY, Gao J, Lieb W, Shieh K, Colford JM Jr: Astragalus-based chinese herbs and platinum-based chemotherapy for advanced non small cell lung cancer: meta-Analysis of randomized trials. J Clin Oncol 2006, 224 (3) : 419–430.CrossRef 6. Wu BC, Xu L, Chen M: Meta-analysis of Ai Di injection combined with NP chemotherapy in the selleck products treatment of late stage non-small cell lung

cancer. Zhejiang Journal of Integrated Traditional Chinese and Western Medicine 2009, 19 (7) : 446–447. 7. Yang LR, Xu XY: Clinical application and curative effect evaluation of Shenqi fuzheng injection. Heilongjiang Journal of Traditional Chinese Medicine PARP inhibitor 2004, 4: 46–48. 8. Lu Y, Lu YX: Clinical application and pharmacology function of Shenqi fuzheng injection. Li Shi Zhen Medicine and material medica research 2006, 17 (10) : 2083–2085. 9. Pan L: Practical road of “”the numeral turn Chinese herbal medicine”" for Shenqi fuzheng injection. Sitaxentan Journal of China Prescription Drug 2009, 1 (82) : 37–39. 10. Zhong ZH: Dictate history: A national

new medicine that come from experiential prescription. Journal of China Prescription Drug 2009, 1 (82) : 33–36. 11. Higgins J, Green S, (eds): Cochrane handbook for systematic reviews of interventions 4.2.6. In the Cochrane library. Volume 301. Wiley: Chichester; 2006. (updated September 2006) 12. WHO: WHO Handbook for Reporting Results of Cancer Treatment. Geneva, Switzerland, World Health Organization; 1979. 13. Yates JW, Chalmer B, McKegney FP: Evaluation of patients with advanced cancer using the Karnofsky performance status. Cancer 1980, 45: 2220–2224.PubMedCrossRef 14. DerSimonian R, Laird N: Meta-analysis in clinical trials. Control Clin Trials 1986, 7: 177–188.PubMedCrossRef 15. Sutton AJ, Abrams KR, Jones DR, Sheldon TA, Song F: Methods for Meta-Analysis in Medical Research. Chichester, United Kingdom, John Wiley & Sons; 2000. 16. Delbaldo C, Michiels S, Syz N: Benefits of adding a drug to a single-agent or a 2-agent chemotherapy regimen in advanced non-small-cell lung cancer: A meta-analysis. JAMA 2004, 292: 470–484.PubMedCrossRef 17. Oremus M, Wolfson C, Perrault A, Demers L, Momoli F, Moride Y: Interrater reliability of the modified Jadad quality scale for systematic reviews of Alzheimer’s disease drug trials. Dement Geriatr Cogn Disord 2001, 12: 232–236.